Lilly Maintains Deal Streak with $1.2B Pact for Hanmi's GLP-2 Candidate

Why It Matters

The partnership gives Lilly a foothold in a high‑unmet‑need niche, diversifying its revenue stream as weight‑loss drugs plateau, while accelerating Hanmi’s entry into global markets.

Key Takeaways

• Lilly licenses Hanmi’s GLP‑2 candidate sonefpeglutide for up to $1.2B.
• Upfront payment $75M; remaining milestones trigger additional funds.
• Deal gives Lilly rights except South Korea for short bowel syndrome drug.
• Expands Lilly’s pipeline beyond GLP‑1 weight‑loss into gastrointestinal therapies.
• Hanmi’s Lapscovery platform also produced approved white‑blood‑cell booster Rolvedon.

Pulse Analysis

Lilly’s $1.2 billion licensing pact with Hanmi Pharm underscores the pharma giant’s strategy to broaden its pipeline beyond the blockbuster GLP‑1 weight‑loss drugs that have driven recent earnings. By securing exclusive rights to sonefpeglutide, a GLP‑2 agonist aimed at short bowel syndrome, Lilly taps into a therapeutic area with limited competition and significant clinical need. The upfront $75 million payment, coupled with milestone‑driven funding, reflects a risk‑balanced approach that leverages Hanmi’s proven Lapscovery platform while preserving Lilly’s capacity to steer later‑stage development and commercialization.

Short bowel syndrome affects patients who have lost large portions of their small intestine, leading to malabsorption and severe nutritional deficits. Existing treatment options are sparse; Takeda’s Gattex remains the only approved GLP‑2 therapy, and recent FDA rejections, such as Zealand Pharma’s glepaglutide, highlight the regulatory hurdles. Sonefpeglutide’s mechanism—promoting intestinal growth and mucosal regeneration—could offer a differentiated benefit, especially if Lilly can demonstrate superior efficacy or safety in upcoming trials. The partnership also positions Hanmi to leverage Lilly’s global manufacturing and sales network, accelerating market entry beyond South Korea.

The agreement fits within Lilly’s broader dealmaking surge, which has included multi‑billion‑dollar vaccine collaborations and a series of oncology licences this year. Such transactions illustrate a shift toward external innovation sourcing, allowing Lilly to diversify its therapeutic portfolio while mitigating R&D risk. For investors and industry observers, the Hanmi deal signals that Lilly is actively pursuing high‑margin, niche indications that complement its core metabolic franchise, potentially stabilizing growth as the weight‑loss market matures.